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Background: Effective interventions to improve immunosuppressive medication adherence among adolescent
and young adult kidney transplant recipients are desperately needed. This paper describes the aims, design,
and methods of the Teen Adherence in Kidney transplant, Effectiveness of Intervention Trial (TAKE-IT) study.
Design and methods: TAKE-IT is a multicentre, prospective, open-label, parallel arm randomized controlled trial
that aims to determine the effectiveness of a clinic-based intervention, including educational, organizational,
and behavioural components, in improving immunosuppressive medication adherence among adolescent and
young adult kidney transplant recipients. Individuals between 11 and 24 years of age who are at least
3 months post-transplant and followed in one of the eight participating pediatric kidney transplant programs, or their
affiliated adult transplant programs are eligible to participate. All participating centers are tertiary care pediatric hospitals
in Canada or the United States. Adherence is monitored using an electronic multi-dose pillbox for all participants
during a 3-month run-in period, followed by a 12-month intervention interval. The primary outcome is ‘taking
adherence’, defined as the proportion of prescribed doses of immunosuppressive medications that were taken,
as measured using electronic monitoring.
All participants meet with the study ‘Coach’ at 3 month intervals. The intervention, administered by trained
lay personnel, targets common adherence barriers. In addition to forming an Adherence Support Team,
intervention participants identify personal barriers to adherence and use Action-focused problem-solving to
address them, have their electronic adherence data fed back to them, and have the option to receive email,
text message, or visual cue dose reminders. Participants in the control group meet with the coach but do
not receive the other components of the intervention. The study aims to have 75 participants in each group
complete the study.
Discussion: Since recruitment began in Feb. 2012, 198 adolescents have been approached to participate, of
whom 130 have completed a baseline visit. As of March 31, 2014, 125 had been randomized, and 86, 68, 61,
and 50 participants had completed 6-month, 9-month, 12-month, and 15-month visits respectively.
Trial registration: Clinicaltrials.gov registration NCT01356277 (May 17, 2011).
Keywords: Adherence, Randomized trial, Adolescent, Intervention, Kidney transplantationBackground
Adolescence and emerging adulthood [1] is a high-risk
period for kidney transplant recipients. Graft failure
rates begin to rise at about 11 years of age, peak in the
interval between 17 and 24 years, and decrease thereafter
[2]. Non-adherence to immunosuppressive therapy may be
the most important factor contributing to poor graft sur-
vival in this age group [3-5]. In a study of pediatric kidney* Correspondence: bethany.foster@mcgill.ca
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unless otherwise stated.transplant recipients, each 10% decrement in adherence
(estimated using the medication possession ratio deter-
mined from claims data) was associated with an 8% higher
hazard of graft failure [6]. Although numerous risk factors
for non-adherence have been identified [7,8], to date no
interventions have been developed that systematically
target these risk factors in the pediatric kidney trans-
plant population.
There are numerous reasons for poor medication adher-
ence. Most non-adherence is ‘unintentional’ [9], and be-
lieved to be related to inadequate organizational skills and/
or problem-solving abilities, or to complexity of the med-
ical regimen. Forgetting was the most commonly statedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lescent renal transplant recipients [10], and the second
most common (29%), after organizational problems
(58%), in another study [11]. Other modifiable risk
factors for non-adherence in adolescents with trans-
plants include lack of parental supervision, poor parent-
patient communication, poor medication and disease
knowledge, lack of pillbox, and complex medication
regimens [3,4,6-8,10,11].
An effective adherence intervention must address the
most common, and most powerful, determinants of
non-adherence. Prior studies of mainly adult transplant
recipients [12] and children and adolescents with other
chronic illnesses [13-15] indicate that effective inter-
ventions include education in conjunction with some
combination of adherence monitoring, promotion of
problem-solving, goal-setting, development of routines,
and/or adherence support. Adherence support from a key
person from outside the healthcare team – called a “per-
sonal trainer” [15] – and text message dose reminders also
show promise in improving adherence [16]. A randomized
trial in 150 adult kidney transplant recipients found sig-
nificantly better adherence and lower hospitalization rates
among patients with behavioural adherence contracts than
among controls [17].
The purpose of this paper is to describe the aims, de-
sign, and methods of TAKE-IT, a multicentre, prospect-
ive, parallel arm, open-label, randomized controlled trial
funded by the American National Institutes of Health,
National Institutes of Diabetes, Digestive and Kidney
diseases (NIDDK; R01DK092977). The study began in
Sept. 2011 and will run until June 2016.Figure 1 Common barriers to medication adherence are indicated, al
address each.Study aims
The primary aim of TAKE-IT is to characterize and com-
pare, over the 12-month intervention interval, adherence
to immunosuppressive medications in the intervention
and control groups.
The TAKE-IT intervention includes educational,
organizational, and behavioural components to tar-
get common adherence barriers (Figure 1), and incor-
porates many of the adherence-promoting strategies
previously identified as helpful in prior trials, and by
families of adolescents with kidney transplants [18]. We
hypothesize that, compared with the control group, the
intervention group will have significantly better adherence
to immunosuppressive medication, which is maintained
over the study interval.
A secondary aim of TAKE-IT is to compare the inter-
vention and control groups with respect to graft out-
comes. Another secondary aim is to identify independent
associations between adherence and healthcare system
factors, including characteristics of the treating team, in-




Figure 2 shows the organizational structure of the 8 kid-
ney transplant centers across Canada and the United
States participating in TAKE-IT. TAKE-IT adheres to
the Declaration of Helsinki, and was approved by the
Research Ethics Boards of all sites (McGill University
Health Centre Research Ethics Board, The Hospital for
Sick Children Research Ethics Board, University of Britishong with the components of the TAKE-IT intervention that
Figure 2 This figure shows the organizational structure of the TAKE-IT study.
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Ethics Board, The Children’s Hospital of Philadelphia
Institutional Review Board, The Washington University in
St. Louis Human Research Protection Office, The Seattle
Children’s Hospital Institutional Review Board, The
Cincinnati Children’s Hospital Medical Center Institutional
Review Board, and the Centre Hospitalier Universitaire
Ste-Justine Research Ethics Board). Informed consent is
obtained from all participants and/or parents.
Study population
TAKE-IT will enrol 176 kidney transplant recipients be-
tween 11 and 24 years old, who are at least 3 mo. post-
transplant, and have a functioning graft. Patients with
neurocognitive disabilities severe enough to preclude par-
ticipation in study procedures, those taking immunuosup-
pressive medications exclusively in liquid formulation, and
those unable to communicate comfortably in English (or
French – Montreal sites only) will be excluded.
Recruitment
Participants will be recruited from the pediatric kidney
transplant clinics at participating centers and their affili-
ated adult clinics over a 30-month interval. The recruit-
ment goal of 176 participants accounts for up to 15%
drop out, with the aim of having at least 150 participants
complete the study.
Baseline assessment
Participants are evaluated at a baseline visit timed to coin-
cide with a regularly scheduled clinic visit. At the baseline
visit, detailed demographic information (sex, race, educationof participant and parents, family structure, household
income, etc.) is collected, in addition to information on
medical history, such as primary kidney disease, type and
duration of renal replacement therapy prior to transplant,
donor source, number of prior transplants, current level
of graft function, and co-morbid conditions. Detailed
information is also collected on immunosuppressive
medications, including dosing times, and on concomi-
tant medications, as well as on accessibility to care.
Participants and their parents complete the validated
adolescent and parent versions of the Medication Barriers
Survey (AMBS and PMBS) [19], the Allocation of Treat-
ment Responsibility (ATR) survey [20], and the Medical
Adherence Measure Medication Module (MAM-MM)
[21]. All questionnaires were translated into French by a
professional translator and underwent basic linguistic
validation [22].
All participants are given an electronic pillbox for ad-
herence monitoring at the baseline visit and taught how
to use it. The dose reminder functions of the pillboxes
are disabled for all participants for the first 3 months of
the study, which constitutes a run-in period. No inter-
vention is applied during the run-in. Figure 3 provides a
timeline of study procedures.
All participants receive usual care from their clinical
treating team. Clinical care providers are free to con-
tinue to use their usual methods of assessing adherence,
and to use their usual methods helping patients to im-
prove adherence. However, no information collected for
study purposes is shared with the treating team. The
study protocol does not dictate the level of parental
involvement in medication administration.
Figure 3 The timeline of study procedures is indicated, including the schedule of intervention and control visits. The first 3 months of
the study constitutes a run-in period during which patients are not yet randomized to the intervention or control group, and no intervention
is applied.
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Participants are randomized at enrolment in age strata
(11–13 y., 14–16 y., 17–19 y., 20–24), by site, in blocks
of 4. Allocation to intervention or control group is
concealed from participants, clinical care providers, and
study personnel at enrolment and during the first two
months of the run-in period. Group allocation is revealed
to study personnel one month prior to the 3-month visit.
Blinding is not feasible to maintain with the proposed
multi-component intervention.
Adherence monitoring
There is no perfect method of measuring adherence; in
the absence of a true gold standard, electronic monitor-
ing is considered the best available method [23]. In the
TAKE-IT study, immunosuppressive medication adher-
ence is monitored using an electronic multi-dose pillbox
that is coupled to a personalized, password-protected,
medication management website. The pillbox is man-
aged by study personnel; participants do not have access
to the website. When an individual compartment of the
pillbox is opened, a signal is sent to the company, and a
date and time ‘stamp’ is recorded in the electronic
record of the patient to whom the device is registered.
The pillbox requires a power supply, but has a back-up
battery with about 8 hours of life.
Because the electronic pillboxes cannot be carried
during daily activities, participants who take medication
doses away from home must remove the medication
from the device prior to leaving home; participants are
asked to either keep a log of medication dosing times
when not at home or to send the study staff a text mes-
sage when they take a dose away from the pillbox [7].
Intervention
The TAKE-IT intervention simultaneously targets several
of the most common barriers to adherence in adolescents,and can be administered as a component of routine clinic
visits through relatively brief interactions between a mem-
ber of the study team, called the ‘Coach’, and the patient
and family.
Participants randomized to the intervention arm
receive education on immunosuppressive medications,
and along with one or both parents and the trained
site Coach, form an Adherence Support Team (AST).
The Coach guides the AST to clarify the responsibility
of each AST member for medication adherence [20],
and uses a novel approach – ‘Action-Focused Problem-
Solving’ – to address personal barriers to adherence
identified as important to the participant using the vali-
dated AMBS/PMBS [19]. Action-focused problem-solving
incorporates two complementary and well-established be-
havioural approaches: problem-solving and implementa-
tion intentions.
Problem-solving skills training enables individuals to
elicit a variety of potentially effective solutions to a prob-
lem and increases the probability that the most effective
solution will be chosen [24,25]. Better problem-solving
skills have been associated with improved adherence across
a number of pediatric populations [14,26,27]. Adherence
interventions aimed at increasing problem-solving skills
have enhanced adherence to life-long treatment regimens
in diabetes, HIV, and asthma [28-30].
Implementation intentions are concrete action plans in
which an individual specifies, in an if-then contingency
format, when, where and how he or she will perform a
behaviour, with the goal of developing habits that promote
adherence [31,32]. Forming implementation intentions
has been shown to make the execution of a plan auto-
matic – to create a habit [33,34]. Applied to medication
adherence, implementation intentions increase the likeli-
hood that a medication is persistently taken on time. Im-
plementation intentions increased medication adherence
by 18% in a randomized controlled trial of adults with
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choose to receive text message, email, or visual cue dose
reminders throughout the study. The initial intervention
visit (~2 hr.) is boosted with briefer (20–30 min.) sessions
at 3-month intervals during which participants review and
update the implementation intentions. At follow-up visits,
the electronic adherence monitoring data from the prior
3 months is reviewed with participants in the intervention
arm in order to help identify days of the week and times
of day that are most problematic, and to guide the devel-
opment and revision of implementation intentions. Feed-
back of adherence data was identified as one of the most
successful methods of improving adherence in a system-
atic review of adherence trials [35].
Control condition
Control participants use the electronic pillbox, and have
study visits with the Coach at the same intervals as inter-
vention participants. During these visits, the participants
are given the opportunity to talk with the Coach in
general terms about their treatment and how they feel it is
going, but adherence is not specifically discussed.
Training and monitoring
Coaches do not require a specific professional background.
However, all Coaches undergo an intensive 2-day, in-
person training session led by a study psychologist. These
training sessions focus on active listening skills and non-
judgmental interaction with patients, and teach coaches to
administer the intervention and control sessions through
didactic sessions and a series of role-plays. Face-to-face
training is followed up with one-on-one phone meetings
with a study psychologist to review areas noted to be in
need of improvement and to make specific plans for add-
itional training if needed. In order to monitor treatment
integrity and coach competency throughout the study,
all of the intervention and control group sessions are
audio-recorded. A supervising psychologist reviews audio-
recordings of the first two administrations of each inter-
vention session by each coach for delivery competency.
Twenty-five percent of the recorded sessions from each site
will be randomly selected and evaluated by a research as-
sistant who is blind to patient identity but not group assign-
ment for intervention fidelity and for competency of
intervention delivery by the study psychologists. If deficien-
cies are identified either with treatment fidelity or compe-
tency, these are addressed directly with the Coach by the
supervising psychologist. Coaches receive monthly supervi-
sion with a licensed clinical psychologist to maintain profi-
ciency levels throughout the course of the project.
Follow-up and retention
All participants are followed up in person, in conjunc-
tion with regular clinic visits, at 3-month intervals overa 15-month period. Study personnel do not share any in-
formation collected for study purposes with the treating
team. Participants receive modest financial compensation
for each study visit attended, as well as token incentive
payments for use of the electronic pillbox (determined
based on evidence that the box is turned on and com-
municating with the server, and being refilled regularly).
Participants also receive study newsletters, birthday, and
holiday cards.Study outcomes
Table 1 indicates the adherence, graft, and adverse out-
comes being measured in all participants. The planned
primary outcome is daily “taking adherence”, defined as
the proportion of daily prescribed doses taken, as mea-
sured using electronic monitoring (EM). Because no one
method of measuring adherence is considered a gold
standard, we will measure adherence in several ways in-
cluding pharmacy dispensing records, self-report using
the MAM-MM, and variability in tacrolimus or siroli-
mus trough levels [36-38]. We will also consider a com-
posite of variability in tacrolimus or sirolimus trough
levels and self-report such as the ‘system for integrated
adherence monitoring’ [39].Additional data
Treating center and healthcare system characteristics
Information [42] regarding practice patterns and charac-
teristics of the healthcare organization will be collected
from each of the sites. Examples include number of kidney
transplant patients followed at the center, whether a dedi-
cated pharmacist or psychologist regularly interacts with
patients as a part of the transplant team, the patient: full-
time transplant nurse ratio, methods that patients may use
to communicate with the treating team (phone/email/text
message), and the frequency of clinic visits and blood mon-
itoring for stable patients. Additional factors [42], indicat-
ing characteristics of the healthcare system within which
the patient is cared for (adult vs. pediatric, Canadian vs.
U.S.), healthcare insurer, medication insurer, and average
monthly out-of-pocket expenses will also be recorded.Accessibility to care
The following information will be collected at enrol-
ment: distance of residence from treating center, and
access to phone/email/text message support from the
treating team. At enrolment, and subsequently every
3 months, participants will be asked if they needed any
of the following but could either not afford to get them,
or the services were unavailable: prescription medica-
tions, medical visits with the transplant team or with a
primary care provider [43,44].




Electronic monitoring Continuously monitored
● Taking adherence (% prescribed doses taken each day)
● Timing adherence (% doses taken within 2 hours of scheduled time each day)
● Drug holidays (missing ≥2 consecutive doses)
Pharmacy refills All refills during study interval
● Taking adherence (% prescribed doses taken over entire intervention period)
Variability in tacrolimus or sirolimus trough levels Monthly levels as measured
for clinical care
● Standard deviation calculated over 6-month intervals
Self-report (Medical Adherence Measure- Medication Module) 3-month intervals
● Taking adherence (% prescribed doses taken, in 3-month intervals)
● Timing adherence (% doses taken within 2 hours of scheduled time, in 3-month intervals)
● Drug holidays (missing ≥2 consecutive doses)
Graft
outcomes
Graft failures or deaths (# failures/person-year of follow-up) All failures during study interval
● Failure defined as loss of graft function requiring return to dialysis or death from any cause
Acute rejections (# rejections/person-year of follow-up) All rejections during study interval
● Biopsy-proven and presumed rejections, defined as rejections diagnosed by the
treating physician based on >20% rise in creatinine
Percent change in estimated glomerular filtration rate (eGFR)*
● Calculated as:
(eGFR at start of intervention – eGFR at study exit) ÷ eGFR at start of intervention
Adverse
outcomes
Deaths All deaths during study interval
Opportunistic viral infections (CMV, EBV, biopsy-proven polyoma virus nephropathy) All infections during study interval
Hospitalizations (# hospitalizations/ person-year of follow-up) All hospitalizations during study interval
Other medical conditions requiring treatment (# conditions/ person-year of follow-up) All conditions during study interval
*eGFR is calculated from height and IDMS-standardized serum creatinine using the updated Schwartz formula [40,41].
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The primary analysis will use intention-to-treat princi-
ples; as-treated secondary analyses will also be done.
Daily taking adherence will be determined for each par-
ticipant for each day of follow-up [45]; the median daily
taking adherence will be determined for participants in
each of the intervention and control groups, and plotted
against time. This will allow assessment of changes in
adherence over the intervention interval for each group.
We will calculate the area under the curve (AUC) for
the entire intervention interval for each group, and com-
pare AUCs using a two-sided, independent two samples
t-test or Wilcoxon test. Greater AUC will reflect greater
adherence. To account for possible imbalances between
groups, and to test for differences in the patterns of
change in taking adherence over time between the inter-
vention and control groups, we will use linear mixed-
effects models, adjusting for potential confounders. We
will use the same approach to analyze the secondary
adherence outcomes.
Percent change in estimated glomerular filration rate
(eGFR) over the intervention interval will be comparedbetween groups using a 2-sided, independent two sam-
ples t-test or a Wilcoxon rank sum test, as appropriate
to the distribution of the data. Acute rejections and graft
failures will each be expressed as a rate per person-
month of observation, and compared between interven-
tion and control groups using Poisson regression.
The multivariable linear mixed-effects models devel-
oped for the primary aim will be extended to include
center and system characteristics and accessibility factors
that are fixed over time (i.e. Canada vs. US), as well as
time-varying center, system, and accessibility variables
(i.e. insurance status, perceived accessibility). Similar
analyses will be undertaken considering secondary adher-
ence outcomes. We will use these models to identify center,
system, and accessibility characteristics that are independ-
ently associated with adherence.
Power considerations
Our preliminary electronic monitoring studies in adolescent
transplant recipients found a mean (±standard deviation
(SD)) taking adherence of 79% ± 33 at one site and 78%± 29
at another site (unpublished). With 75 participants per
Table 2 Baseline demographic and disease/treatment
characteristics of participants randomized to date
Control Intervention
n 64 61
Male (%) 39 (60.9) 34 (55.7)
Median age (IQR) 15.9 (13.6 – 17.5) 16.2 (14.0 – 17.8)
Race (%)
White 42 (65.6) 43 (70.5)
Black 9 (14.1) 6 (9.8)
Asian 4 (6.3) 3 (4.9)
American Indian/Alaska Native 2 (3.1) 1 (1.7)
Hawaiian/Other Pacific Islander 2 (3.1) 0 (0)
Other 5 (7.8) 8 (13.1)
Hispanic (%) 4 (6.3) 7 (11.5)
Median years since transplant (IQR) 3.7 (0.8-7.5) 4.4 (1.5-8.4)
Primary disease (%)
CAKUT 30 (46.9) 21 (34.4)
Glomerulonephritis 3 (4.7) 6 (9.8)
FSGS 6 (9.4) 9 (14.8)
Other 23 (35.9) 21 (34.4)
Missing 2 (3.1) 4 (6.6)
Number of immunosuppressive
medications (%)
1 3 (4.7) 4 (6.6)
2 27 (42.2) 21 (34.4)
3 34 (53.1) 35 (57.4)
4 0 (0.0) 1 (1.6)
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tect a 20% difference in taking adherence, using a two group
t-test, assuming a common SD of 32 (40% of the mean).
Preliminary studies suggested substantially lower variability
in adherence after intervention compared with before. If the
SD is 25% in the intervention group, and 40% in the control
group, we will have 95% power to detect a 20% difference in
taking adherence, or 80% power to detect a 16% difference.
Based on preliminary studies indicating a 26% improvement
in adherence after intervention with dose reminders,
and on published work [12], it is reasonable to expect
a 20% improvement in adherence when a single level
intervention is applied. Effect sizes may be larger with
a multi-level intervention.
Due to low event rates and large variability in graft
function, statistical power is extremely limited to detect
differences between intervention and control groups for
graft outcomes; these analyses are considered exploratory.
Progress
Recruitment began in February 2012. Figure 4 shows the
numbers of patients in the eligible age range who were
screened, enrolled, and randomized to date. As of March
31, 2014, 130 of the 198 adolescents who were approached
had agreed to participate (66%). Table 2 shows the demo-
graphic, medical, and treatment characteristics, by group,
of the 125 participants with known randomization alloca-
tion to date. Reasons for refusal fall into 3 general categor-
ies: 25% refused to meet with study personnel to hear
more about the study; 50% felt that they had no problem
















Figure 4 As of March 31, 2014, 268 patients in the eligible age
range had been screened for participation. Of these, 70 met
exclusion criteria (including significant neurocognitive disability,
inability to communicate in English or French, imminent graft failure,
imminent transfer to adult care). Of the 198 who were eligible to
participate, 130 agreed (66%) and had completed a baseline visit.
Randomization occurs 1 month before the 3-month visit; 125 participants
had been randomized as of March 31, 2014.
Median total number of
all medications (IQR)
6 (5 - 9) 7 (5 - 9)
CAKUT Congenital anomalies of the kidneys and urinary tract, FSGS Focal and
segmental glomerulosclerosis.25% felt it would take too much time or would add
expense.
Discussion
A 2008 U.S. National Institutes of Health consensus
conference on immunosuppressive medication non-
adherence highlighted the consequences of and risk fac-
tors for non-adherence, and made an urgent call for ad-
equately powered randomized trials to test interventions
to improve adherence in the high-risk adolescent trans-
plant population [8]. TAKE-IT was designed to address
the need for effective interventions to improve medica-
tion adherence in youth with kidney transplants.
An important feature of the TAKE-IT intervention is
that it is administered repeatedly at regular intervals –
an intervention approach [46,47] demonstrated to offer
better sustained treatment effects than interventions de-
livered in single session or concentrated formats [48,49].
Repeated intervention sessions provide an opportunity
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the intervention, but can pre-empt new barriers to pre-
vent future non-adherence, as barriers change over time
[7,21]. A similar ‘continuous self-improvement’ adher-
ence intervention approach in adult kidney transplant
recipients, involving regular contact with participants,
showed promise [50]. Furthermore, the TAKE-IT inter-
vention is clinic-based, and integrated with usual clinical
care, making it feasible for application in practice. It
may be possible to include lay coaches, supported by a
psychologist, into the clinical care team to support ad-
herence. The feasibility of widespread use of EM devices
in clinical practice will require further study.
In addition to determining the effectiveness of the
intervention, this study will provide important informa-
tion on the time and resources needed to apply such an
intervention as a part of clinical care. It will not be
possible for us to determine which component(s) of the
TAKE-IT intervention are most powerful in promoting
adherence. However, if effective, this will be the first
intervention demonstrated to improve adherence in a
randomized trial for adolescent kidney transplant recipi-
ents, and as such will represent a major advance in the
standard of care. Future studies will refine intervention
strategies.
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